Dr Reddy's IRS penalty disclosure, filed with BSE on October 3, 2026, reported that its step-down wholly owned US subsidiary, Dr. Reddy’s Laboratories, Inc., received a final transcript classifying $32,350.20 as a penalty. The company attributed the penalty to a misclassification of the fiscal-year reference when making a tax payment.

The subsidiary, referred to in the filing as DRL Inc., received the communication on October 2, 2026. The transcript itself was dated September 25, 2026, and came from the Department of the Treasury, Internal Revenue Service, Cincinnati, Ohio, US.

Dr Reddy’s said its evaluation showed no material impact on the company’s financials, operations or other activities. That assessment accompanied the disclosure of the penalty amount and the reason cited for the action.

Penalty linked to fiscal-year reference

The filing identifies the issue as a misclassification of the fiscal-year reference at the time of tax payment. It lists this same issue both as the reason for the penalty and as the details of the violation or contravention reported to exchanges.

The disclosed action concerns DRL Inc., the step-down wholly owned subsidiary. The parent company reported the action through its exchange filing, while identifying the US subsidiary as the recipient of the IRS transcript.

The sequence of dates distinguishes the authority’s document from its receipt and subsequent disclosure:

  • September 25, 2026: Date of the final IRS transcript.
  • October 2, 2026: DRL Inc. received the transcript.
  • October 3, 2026: Dr Reddy’s disclosed the matter to exchanges.

Exchange disclosure details

The company submitted the intimation under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, read with Schedule III, Paragraph A, Sub-paragraph 20.

The communication was addressed to the National Stock Exchange of India, BSE, the New York Stock Exchange and NSE IFSC. It identified the company’s BSE scrip code as 500124, its NSE and NSE IFSC code as DRREDDY, and its NYSE stock code as RDY.

K Randhir Singh, Company Secretary, Compliance Officer and Head-CSR, signed the filing on behalf of Dr. Reddy’s Laboratories Limited.